ATOSSA THERAPEUTICS, INC.
ATOSNasdaq
$2.49
↑ +4.2%Jul 17 close · end-of-day
Price
1Y↓ -81.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$21.5M
Enterprise Value
-$10.2M
P/E
—
P/S
—
P/B
0.7
EV/EBITDA
—
PEG
—
FCF Yield
-155.6%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$37.6M
Free Cash Flow (TTM)
-$33.4M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-123.5%
ROIC
—
Debt / Equity
—
Net Cash
$31.7M
Return 1Y
-80.9%
Company profile
Atossa Therapeutics, Inc. focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxefen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized patients.
- CEO
- Steven C. Quay
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 8
- Headquarters
- Washington
- Website
- atossatherapeutics.com
Management & directors
- Quay Steven CPresident & CEO
- Daniel Mark JamesChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
ATOS Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$1.11↑ +42.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$14.6M | -$20.5M | -$27.7M | -$31.4M | -$27.6M | -$37.1M |
| Net income | -$17.8M | -$20.6M | -$27.0M | -$30.1M | -$25.5M | -$34.8M |
| Diluted EPS | — | — | -$0.21 | -$0.24 | -$3.04 | -$4.04 |
| Operating cash flow | -$11.6M | -$16.5M | -$20.8M | -$20.9M | -$21.0M | -$29.8M |
| Free cash flow | -$11.6M | -$16.5M | -$20.8M | -$21.0M | -$21.0M | -$29.8M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$7.1M | -$6.4M | -$7.2M | -$7.4M | -$9.0M | -$9.3M | -$11.4M | -$9.9M |
| Net income | -$6.0M | -$7.2M | -$6.3M | -$6.7M | -$8.4M | -$8.7M | -$10.9M | -$9.6M |
| Diluted EPS | -$0.05 | -$0.06 | -$2.88 | -$0.78 | -$0.07 | -$0.07 | -$3.12 | -$1.11 |
| Operating cash flow | -$4.5M | -$4.8M | -$7.1M | -$6.0M | -$7.3M | -$6.0M | -$10.5M | -$9.6M |
| Free cash flow | -$4.5M | -$4.8M | -$7.1M | -$6.0M | -$7.3M | -$6.0M | -$10.5M | -$9.6M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jun 11, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-12 | Steinhart Richard I | Award | 10,000 | $0.00 | $0.00 | filing |
| 2026-05-12 | Chen Shu-Chih | Award | 10,000 | $0.00 | $0.00 | filing |
| 2026-05-12 | Remmel H. Lawrence | Award | 10,000 | $0.00 | $0.00 | filing |
| 2026-05-12 | Finn Jonathan | Award | 10,000 | $0.00 | $0.00 | filing |
| 2026-05-12 | Galli Stephen J | Award | 10,000 | $0.00 | $0.00 | filing |
| 2026-05-12 | Cigler Tessa | Award | 10,000 | $0.00 | $0.00 | filing |
| 2026-03-27 | QUAY STEVEN C· President & CEO | Award | 65,000 | $0.00 | $0.00 | filing |
| 2026-03-26 | Daniel Mark James· Chief Financial Officer | Award | 63,000 | $0.00 | $0.00 | filing |
| 2026-01-20 | QUAY STEVEN C· President & CEO | Award | 331,674 | $0.00 | $0.00 | filing |
| 2026-01-20 | QUAY STEVEN C· President & CEO | Award | 325,203 | $0.00 | $0.00 | filing |
Latest 10 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.